Specific duties include: Ready to put this into practice
Roshanravan B, Liu SZ, Ali AS, Shankland EG, Goss C, Amory JK, et al
Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
Mitochondrial metabolism and homeostasis Mitochondrial dysfunction is a core feature of DACI (70), contributing to both the ROS production and iron dysregulation that drive ferroptosis
IGF-1 LR3 (Long Arginine 3-IGF-1) Side Effects Hypoglycemia, retina swelling, muscle pain, joint pain bell's palsy